Abstract
Asthma and COPD are the most frequent chronic respiratory diseases. Although they have different characteristics, some individuals share features of both diseases, which has been called the asthma-COPD overlap syndrome (ACOS). Although there is not a universally accepted definition for ACOS, it was initially defined as symptoms of increased variability of airflow in association with an incompletely reversible airflow obstruction. The most recent COPD guidelines include this phenotype and its diagnostic features. Patients with ACOS are usually characterized by increased reversibility of airflow obstruction, eosinophilic bronchial and systemic inflammation, and increased response to inhaled corticosteroids, compared with COPD patients. The relevance of the ACOS is the need to identify patients with COPD who may have underlying eosinophilic inflammation that responds better to inhaled corticosteroids. Until new diagnostic tools are developed, a previous diagnosis of asthma in a patient with COPD can be a reliable criterion to suspect ACOS in a patient with COPD but a comprehensive approach may be required in most cases for a definitive diagnosis of ACOS.
Highlights
Chronic obstructive pulmonary disease (COPD) is an underdiagnosed disease with a high morbidity and mortality and is a very significant public health problem
Fu et al [26] examined the levels of the systemic inflammation markers PCR and IL-6 in asthma, COPD and asthma-COPD overlap syndrome (ACOS) patients and identified potential clinical characteristics that were associated with these biomarkers
They found a high prevalence of systemic inflammation in older people with ACOS and an elevated IL-6 compared with asthma patients
Summary
Asthma and COPD are the most frequent chronic respiratory diseases. They have different characteristics, some individuals share features of both diseases, which has been called the asthma-COPD overlap syndrome (ACOS). Patients with ACOS are usually characterized by increased reversibility of airflow obstruction, eosinophilic bronchial and systemic inflammation, and increased response to inhaled corticosteroids, compared with COPD patients. The relevance of the ACOS is the need to identify patients with COPD who may have underlying eosinophilic inflammation that responds better to inhaled corticosteroids. Until new diagnostic tools are developed, a previous diagnosis of asthma in a patient with COPD can be a reliable criterion to suspect ACOS in a patient with COPD but a comprehensive approach may be required in most cases for a definitive diagnosis of ACOS
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.